NuCana’s NUC-3373 Shows Promise in Cancer Treatment

Nucana (NCNA) has released an update.

NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with advanced solid tumors and lung cancer, respectively. Notably, patients who had exhausted other treatments demonstrated significant tumor reduction and prolonged progression-free survival. These developments could position NUC-3373 as a valuable option for hard-to-treat cancer cases, potentially impacting NuCana’s market performance.

For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.